{"id":109683,"date":"2026-01-23T12:33:20","date_gmt":"2026-01-23T12:33:20","guid":{"rendered":"https:\/\/www.newsbeep.com\/us-ny\/109683\/"},"modified":"2026-01-23T12:33:20","modified_gmt":"2026-01-23T12:33:20","slug":"igc-pharma-adds-new-york-site-for-alzheimers-disease-trial","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us-ny\/109683\/","title":{"rendered":"IGC Pharma adds New York site for Alzheimer\u2019s disease trial"},"content":{"rendered":"<p>                                    <img decoding=\"async\" src=\"https:\/\/www.newsbeep.com\/us-ny\/wp-content\/uploads\/2026\/01\/CTA-23-01-2026-Located-at-2409-Ocean-Avenue-Unit-1F-Brooklyn-New-York-430x241.jpg\" alt=\"\"\/><\/p>\n<p>                                    IGC incorporates AI to optimise trials, enhance patient targeting, and accelerate drug discovery. Credit: IGC Pharma.<\/p>\n<p class=\"drop-cap\">IGC Pharma has expanded its CALMA Phase II clinical trial by adding Integrative Clinical Trials, based in Brooklyn, New York, US, as a new site evaluating IGC-AD1 for agitation associated with Alzheimer\u2019s disease.<\/p>\n<p>Integrative Clinical Trials conducts studies across a broad range of central nervous system (CNS) disorders, including mild cognitive impairment and Alzheimer\u2019s.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.clinicaltrialsarena.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/GMS-logo.svg\" alt=\"\"\/> Discover B2B Marketing That Performs <\/p>\n<p>\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n<p><a href=\"https:\/\/www.globaldatamarketingsolutions.com\/\" class=\"gms-find-out-more\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n\t\t\t\t\t\t\tFind out more <\/a><\/p>\n<p>The site is led by principal investigator Dr Inna Yuryev-Golger, who has more than ten years of experience in clinical research, and Bella Yevseva, who serves as clinical trial coordinator.<\/p>\n<p>The centre enhances IGC Pharma\u2019s access to a diverse patient population in a major metropolitan area. The company stated that bringing in sites with CNS experience is central to supporting enrolment and patient engagement for the ongoing study.<\/p>\n<p>IGC-AD1 is an investigational cannabinoid-based therapy being studied in a double-blind, placebo-controlled, randomised Phase II clinical trial for patients experiencing agitation related to Alzheimer\u2019s.<\/p>\n<p>The ongoing expansion of the CALMA trial\u00a0demonstrates IGC Pharma\u2019s efforts to facilitate patient enrolment and ensure comprehensive clinical monitoring during the study.<\/p>\n<p>IGC develops therapies for Alzheimer\u2019s and metabolic disorders using AI. Its pipeline includes TGR-63 (targeting amyloid plaques), IGC-AD1, and additional early-stage programmes focused on tau proteins, metabolic dysfunctions, and neurodegeneration.<\/p>\n<p>IGC CEO Ram Mukunda said: \u201cAdding Integrative Clinical Trials further strengthens our CALMA clinical network with a site that has deep expertise across CNS disorders.<\/p>\n<p>\u201cTheir experience in neuropsychiatric and neurodegenerative research supports our commitment to high-quality data generation and efficient trial execution as we advance IGC-AD1.\u201d<\/p>\n<p>In 2024, IGC Pharma <a href=\"https:\/\/www.clinicaltrialsarena.com\/news\/igc-pharma-alzheimers-trial\/\" target=\"_blank\" rel=\"nofollow noopener\">reported the enrolment<\/a> of two subjects at Neurostudies, a clinical research site in Port Charlotte, Florida, US, for its Phase II trial of IGC-AD1 to treat agitation in Alzheimer\u2019s.<\/p>\n<p>                    <img decoding=\"async\" src=\"https:\/\/www.clinicaltrialsarena.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/newsletter-new.svg\" alt=\"Email newsletter icon\"\/><\/p>\n<p>\n                    Sign up for our daily news round-up!<br \/>\n                    Give your business an edge with our leading industry insights.\n                <\/p>\n","protected":false},"excerpt":{"rendered":"IGC incorporates AI to optimise trials, enhance patient targeting, and accelerate drug discovery. Credit: IGC Pharma. IGC Pharma&hellip;\n","protected":false},"author":2,"featured_media":109684,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[49253,9,11,10],"class_list":{"0":"post-109683","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-new-york","8":"tag-clinical-trials","9":"tag-new-york","10":"tag-new-york-headlines","11":"tag-new-york-news"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-ny\/wp-json\/wp\/v2\/posts\/109683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-ny\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-ny\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-ny\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-ny\/wp-json\/wp\/v2\/comments?post=109683"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-ny\/wp-json\/wp\/v2\/posts\/109683\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-ny\/wp-json\/wp\/v2\/media\/109684"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-ny\/wp-json\/wp\/v2\/media?parent=109683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-ny\/wp-json\/wp\/v2\/categories?post=109683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-ny\/wp-json\/wp\/v2\/tags?post=109683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}